Synlogic Inc

Synlogic Inc. a clinical-stage biopharmaceutical company engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618 an orally administered non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934 an orally administered non-systemically absorbed drug candidate which is in Phase III clinical trial to treat phenylketonuria; SYNB1353 an orally administered non-systemically absorbed drug candidate which is in Phase II clinical to treat homocystinuria; SYNB8802 an orally administered non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891 an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks Inc. Synlogic Inc. is based in Cambridge Massachusetts.